Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: J Rheumatol. 2016 Dec 1;44(4):505–511. doi: 10.3899/jrheum.161003

Table 2.

Change from Baseline to Week 36 MI AC p-value
Improvement in SF36 physical function
 Opioid users 10.25 (1.94) 7.00 (1.87) 0.234
 Opioid non-users 14.47 (1.23) 9.66 (1.22) 0.006*
Reduction in BPI pain severity
 Opioid users -0.80 (0.17) -0.76 (0.16) 0.930
 Opioid non-users -1.49 (0.12) -0.98 (0.12) 0.004*
Improvement in global FM severity (FIQ total)
 Opioid users -9.60 (1.71) -9.49 (1.66) 0.963
 Opioid non-users -15.47 (1.21) -11.85 (1.20) 0.036*
Increase in light-moderate physical activity#
 Opioid users 3.64 (0.84) 3.26 (0.82) 0.746
 Opioid non-users 4.68 (0.52) 3.01 (0.51) 0.023*

Values are means (standard errors) adjusted for baseline outcome and body mass index

*

P<0.05; Analyses included subjects (N=198, 92% of 216) with 6-month follow-up data.

#

Number of hours per week

MI=motivational interviewing, AC=Attention control